You are here: Industry Insights > Valeant

News List

FDA's generic competition push hits Valeant's Isuprel, a price-hike poster child fiercepharma
August 08, 2017
The FDA has approved a generic to Isuprel, a heart drug whose price rocketed up more than 300% after Valeant bought it from Marathon.
Valeant to sell Obagi medical products business for $190m pharmaceutical-technology
July 20, 2017
Valeant Pharmaceuticals International has entered an agreement through certain affiliates to divest its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund for $190m.
Valeant Agrees to Sell Obagi Medical Products Business americanpharmaceuticalreview
July 18, 2017
Valeant Pharmaceuticals announced certain affiliates of the company have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund.
Sanpower Group completes acquisition of Dendreon from Valeant pharmaasia
July 13, 2017
Chinese company completes acquisition of U.S. firm providing FDA-approved cellular immunotherapy for prostate cancer.
Valeant completes sale of Dendreon to Sanpower for $819.9m pharmaceutical-technology
July 04, 2017
Canadian company Valeant Pharmaceuticals International has completed the sale of all outstanding equity interests in its subsidiary Dendreon Pharmaceuticals to the Sanpower Group for $819.9m.
Valeant announces sale of iNova Pharmaceuticals for $930 million europeanpharmaceuticalreview
June 20, 2017
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
Valeant Announces Leadership Changes americanpharmaceuticalreview
May 09, 2017
Valeant Pharmaceuticals announced appointments to the dermatology leadership team of Michael McMyne as vice president of Sales, and Stacey Williams as vice president of Marketing. Additionally, the company announced Lainie Keller has joined as vice presid
Bausch + Lomb and Nicox Announce PDUFA Date for Novel Glaucoma Candidate Latanoprostene Bunod americanpharmaceuticalreview
March 22, 2017
Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of August 24, 2017...
Ackman unloads entire stake in Valeant firstwordpharma
March 14, 2017
Pershing Square Capital Management CEO Bill Ackman stated Monday that his hedge fund sold all its shares in Valeant Pharmaceuticals, sending the drugmaker's stock down as much as 9 percent.
Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement firstwordpharma
March 13, 2017
Valeant Pharmaceuticals International announced that it has obtained the requisite lender approval for the previously announced amendment of the Company's existing credit agreement...

Previous page 1 2 3 Next page